CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 122,975	$ 131,329
Marketable securities	464,109	510,094
Interest receivable	974	1,035
Accounts receivable	6,746	5,224
Prepaid expenses and other current assets	12,140	11,986
Total current assets	606,944	659,668
Marketable securities, non-current	42,431	50,530
Property and equipment, net	45,222	41,324
Intangible assets	55,583	58,128
Goodwill	40,994	42,798
Operating lease right-of-use assets	70,324	71,045
Other non-current assets	14,097	13,557
Restricted cash	1,500	1,500
Total assets	877,095	938,550
Current liabilities:
Accounts payable	11,638	12,553
Accrued compensation and employee benefits	13,077	20,738
Other accrued liabilities	13,760	18,612
Deferred revenues	94,364	91,644
Total current liabilities	132,839	143,547
Deferred revenues, non-current	222,278	245,045
Long-term portion of lease liabilities	38,463	38,396
Deferred income tax	6,870	7,185
Other non-current liabilities	7,228	7,011
Total liabilities	407,678	441,184
Commitments
Stockholders’ equity:
Preferred stock	0	0
Common stock	1,437	1,421
Additional paid-in capital	1,292,118	1,269,375
Accumulated deficit	(823,914)	(777,981)
Accumulated other comprehensive income	714	5,419
Total Sangamo Therapeutics, Inc. stockholders’ equity	470,355	498,234
Non-controlling interest	(938)	(868)
Total stockholders’ equity	469,417	497,366
Total liabilities and stockholders’ equity	$ 877,095	$ 938,550